Researchers in China have discovered a new therapeutic target, and identified a rapid-acting lead compound that may overcome the drawbacks of current antidepressants. The research team, based at Nanjing Medical University’s School of Pharmacy, designed a fast-acting antidepressant that works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus. The dorsal raphe nucleus (DRN) of the midbrain influences a number of central nervous system processes, and the main transmitter of the DRN is serotonin, the primary target for most antidepressants. Neurons communicate with each other by releasing a series of neurotransmitters into the synaptic space, and these transmitted electrical signals ultimately determine feelings, thoughts and actions, explained co-lead study author Qi-Gang Zhou. The study was published in Science on Oct. 28, 2022. Read More
Researchers from the University of Zaragoza and Promontory Therapeutics Inc. have discovered that PT-112, which has a multimodal mechanism of action, could have different clinical applications in cancer treatment due to its effects on mitochondria in castration-resistant prostate cancer (CRPC). PT-112 is an immunogenic small molecule currently in phase II development in metastatic castration-resistant prostate cancer (mCRPC). The researchers designed PT-112 to target advanced solid tumors, such as thymus, small-cell, non-small-cell lung or CRPC.
Read More
Researchers from Duality Biologics (Suzhou) Co. Ltd. presented preclinical data for a novel Trop-2-targeting antibody-drug conjugate (ADC), DB-1305, being developed for the treatment of solid tumors. Read More
The Undiagnosed Diseases Network uncovered three unrelated individuals with mutations in the gene encoding serine palmitoyltransferase small subunit A (SPTSSA). Read More
Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. have disclosed salts of NAD+ ADP-ribosyltransferase poly [ADP-ribose] polymerase (PARP) inhibitors reported to be useful for the treatment of cancer, bone, cardiovascular, immunological, inflammatory and respiratory disorders, metabolic diseases and thrombosis. Read More
The University of Basel has synthesized triazine derivatives acting as phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders. Read More
Turnstone Biologics Corp. has received IND clearance from the FDA for the company's lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01. Read More
Lifearc has identified pyrimidine compounds acting as serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of chronic myeloid leukemia. Read More
Shandong Luye Pharmaceutical Co. Ltd. has divulged cannabidiol prodrugs reported to be useful for the treatment of cancer, tremor, epilepsy, anxiety disorder, inflammatory disorders, pain, multiple sclerosis and Parkinson's disease, among others. Read More
Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson). Read More
Hainan Sparkle Therapeutics Co. Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer. Read More
